Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 74

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 74
---
 RSUs as these awards have no exercise price. (4) Includes 3,447,685 ordinary shares available under our Employee Share Purchase Plan. (5) Pursuant to its terms, our sole non-shareholder approved plan, the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan (“2014 Plan”), expired in October 2024 upon reaching the end of its 10-year term. As a result, no additional shares will be issued under the 2014 Plan, although awards previously granted under the 2014 Plan will remain outstanding in accordance with their terms. The 2014 Plan was a non- shareholder approved plan, which was adopted by our board of directors on October 22, 2014 and is intended to satisfy the requirements of Nasdaq Listing Rule 5635(c)(4) or any successor thereto. The 2014 Plan provided for grants of nonstatutory share options, share appreciation rights, restricted shares and share units were available for grant under the 2014 Plan to new employees of Theravance Biopharma, prior to its expiration in October 2024. Our board of directors authorized 750,000 of our ordinary shares for issuance under the 2014 Plan. All option grants made pursuant to the 2014 Plan had an exercise price per share of no less than 100% of the fair market value per ordinary share on the grant date. Each option or other equity incentive award granted pursuant to the 2014 Plan vested in installments over the holder’s period of service with us. Additional features of the 2014 Plan are described in Note 11 and Part II, Item 5 of our consolidated financial statements in our Annual Report on Form 10-K filed on March 7, 2025.

48

TABLE OF CONTENTS RELATED PARTY TRANSACTIONS In addition to the compensation arrangements with our directors and executive officers described elsewhere in this proxy statement, the following is a description of each transaction since January 1, 2024 and each currently proposed transaction in which: • we have been or are to be a participant; • the amount involved exceeds or will exceed $120,000; and • any of our directors, executive officers or holders of more than 5% of our shares, or any immediate family member of or person sharing the household with any of these individuals (other than tenants or employees), had or will have a direct or indirect material interest. Indemnification Agreements We have entered into indemnification